NRx Pharmaceuticals, Inc.
11:45 AM - 12:00 PM (EDT), Thursday, June 8, 2023 ・ Session Room 104A
Clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain’s NMDA receptor and is being investigated in a Phase 3 trial under an FDA Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and suicidal ideation, an indication for which the only approved treatment is electroshock therapy.
Ticker:
NRXP
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Delaware
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
NRX-101
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
